Möchten Sie immer auf dem neuesten Stand bleiben?

Vivani Medical entered into agreement with Novo Nordisk to evaluate its miniature subdermal semaglutide (GLP-1) implant for weight management

Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535

Burntide Gummies supplement facts panel, Apple Cider Vinegar and BHB salt ingredient details, and customer service contacts are outlined.

Cosmos Health advances its wholly owned CCX0722 hydrogel weight management patent application across the U.S., Europe, Australia, and Canada.

Novo Nordisk's Wegovy® pill has been approved in the UK as an adjunct to a reduced-calorie diet and increased physical activity for adults

Novo Nordisk is launching Wegovy® pill in the UAE, the first country outside the US, to make the Wegovy® pill available to people living with obesity

Arlington, VA, June 01, 2026 (GLOBE NEWSWIRE) -- New online community brings together people navigating GLP-1 medications, diabetes, obesity, metabolic health, and related conditions to learn,...

Felix expands lower-cost GLP-1 access, offering Ozempic at generic-level pricing with free-start program and ongoing clinical support

CHMP under (EMA) has adopted a positive opinion, recommending marketing authorisation of Wegovy® pill to reduce excess body weight

Dublin, May 21, 2026 (GLOBE NEWSWIRE) -- The "Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2026" has been added to ResearchAndMarkets.com's offering. The glucagon-like...